Treatment of Overactive Bladder Symptoms with Extended Release Fesoterodine Fumarate
نویسندگان
چکیده
Fesoterodine extended-release (brand name Toviaz) is a new competitive muscarinic receptor antagonist labeled for the treatment of overactive bladder (OAB). Here we have undertaken a substantial update to a systematic review evaluating the effects of fesoterodine in the treatment of OAB. Our results indicate that fesoterodine was found to have significant improvements in the management of OAB symptoms compared with placebo. Post hoc analysis of these trials demonstrated significant improvements in health-related quality of life in patients with overactive bladder. Only one study included tolterodine, and direct comparisons between fesoterodine and tolterodine were not conducted. The most common treatment-emergent adverse effects associated with fesoterodine included dry mouth and constipation. In summary, fesoterodine appears to be effective and generally safe for the treatment of overactive bladder. Nonetheless, additional comparative trials are required to evaluate whether fesoterodine provides a substantial advantage over extended-release tolterodine.
منابع مشابه
Fesoterodine fumarate for the treatment of overactive bladder in the elderly – a review of the latest clinical data
Overactive bladder is a common and troublesome condition for many older people. Although the first-line treatment for the condition is with behavioral and lifestyle measures, many older people will require pharmacological therapy to successfully manage their condition. Fesoterodine, a relatively new antimuscarinic agent for the treatment of overactive bladder, has been extensively trialed in ol...
متن کامل[New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder].
OBJECTIVE Evaluate the effect of the treatment with fesoterodine fumarate in patients with overactive bladder, as an alternative in case of failure of the usual anticholinergic treatment, due to either lack of therapeutic efficacy or due to intolerance to side effects. MATERIAL AND METHOD A retrospective review of 158 patients with overactive bladder was carried out. The patients were divided...
متن کاملDose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
BACKGROUND Previous randomized studies have demonstrated that fesoterodine significantly improves the Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release (ER). This study aimed to assess the effect of aging and dose escalation on patient-reported treatment benefit, after changing their first Overactive Bladder (OAB) therapy with tolterod...
متن کاملEffects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
AIMS To evaluate the efficacy and tolerability of flexible-dose fesoterodine in subjects with overactive bladder (OAB) who were dissatisfied with previous tolterodine treatment. METHODS This was a 12-week, open-label, flexible-dose study of adults with OAB (> or = 8 micturitions and > or = 3 urgency episodes per 24 h) who had been treated with tolterodine (immediate- or extended-release) for ...
متن کاملEfficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
AIMS To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg. METHODS In a 12-week, double-blind trial, subjects with self-reported OAB symptoms for ≥ 6 months, mean of ≥ 8 micturitions and ≥ 2 to < 15 urgency urinary incontinence (UUI) episodes/24 h, and suboptimal response t...
متن کامل